Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection

We estimated 30-day all-cause and Clostridium difficile infection (CDI)–associated hospital readmissions in participants at high risk of recurrent CDI enrolled in MODIFY I/II. Bezlotoxumab-treated inpatients experienced fewer CDI-associated readmissions compared with placebo-treated inpatients, nota...

Descripción completa

Detalles Bibliográficos
Autores principales: Prabhu, Vimalanand S, Cornely, Oliver A, Golan, Yoav, Dubberke, Erik R, Heimann, Sebastian M, Hanson, Mary E, Liao, Jane, Pedley, Alison, Dorr, Mary Beth, Marcella, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5848255/
https://www.ncbi.nlm.nih.gov/pubmed/30060024
http://dx.doi.org/10.1093/cid/cix523

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5848255/
https://www.ncbi.nlm.nih.gov/pubmed/30060024
http://dx.doi.org/10.1093/cid/cix523

Ejemplares similares